Latest Breaking News On - Gideonm hirschfield - Page 1 : comparemela.com

Study explores potential target to treat liver disease

Seladelpar normalizes ALP, reduces pruritis vs. placebo in primary biliary cholangitis

Study shows seladelpar beneficial for patients with primary biliary cholangitis

Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023

Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 Pliant Therapeutics, Inc. , a clinical-stage.

CymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2023

/PRNewswire/ CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.